Ubiquitination Insight from Spinal Muscular Atrophy—From Pathogenesis to Therapy: A Muscle Perspective
Abstract
:1. Introduction
2. Spinal Muscular Atrophy (SMA)
3. Ubiquitination, the Master Regulator of Protein Stability
4. Role of E3 Ligases in Muscle Atrophy Development
4.1. MuRF1 and Atrogin-1
4.2. E3 Ligases Associated with MuRF-1 and Atrogin-1
4.3. PI3K/AKT and Other Guardians of Muscle Mass
5. FOXOs as Regulators of Muscle Mass
5.1. The Interplay between FOXO and Ubiquitination
5.2. β-Catenin and AMPK: Partners of FoxO in Atrophy
6. Changes in Ubiquitination in SMA
7. UPS-Directed Approaches in SMA Therapeutics
Author Contributions
Funding
Conflicts of Interest
References
- Perez-Baos, S.; Prieto-Potin, I.; Roman-Blas, J.A.; Sanchez-Pernaute, O.; Largo, R.; Herrero-Beaumont, G. Mediators and Patterns of Muscle Loss in Chronic Systemic Inflammation. Front. Physiol. 2018, 9, 409. [Google Scholar] [CrossRef] [PubMed]
- Pang, X.; Zhang, P.; Chen, X.; Liu, W. Ubiquitin-proteasome pathway in skeletal muscle atrophy. Front. Physiol. 2023, 14, 1289537. [Google Scholar] [CrossRef]
- Ferreira, R.P.; Duarte, J.A. Protein Turnover in Skeletal Muscle: Looking at Molecular Regulation towards an Active Lifestyle. Int. J. Sports Med. 2023, 44, 763–777. [Google Scholar] [CrossRef]
- Murach, K.A.; Fry, C.S.; Dupont-Versteegden, E.E.; McCarthy, J.J.; Peterson, C.A. Fusion and beyond: Satellite cell contributions to loading-induced skeletal muscle adaptation. FASEB J. 2021, 35, e21893. [Google Scholar] [CrossRef]
- Brzustowicz, L.M.; Lehner, T.; Castilla, L.H.; Penchaszadeh, G.K.; Wilhelmsen, K.C.; Daniels, R.; Davies, K.E.; Leppert, M.; Ziter, F.; Wood, D.; et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature 1990, 344, 540–541. [Google Scholar] [CrossRef]
- Lefebvre, S.; Burglen, L.; Reboullet, S.; Clermont, O.; Burlet, P.; Viollet, L.; Benichou, B.; Cruaud, C.; Millasseau, P.; Zeviani, M.; et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80, 155–165. [Google Scholar] [CrossRef] [PubMed]
- Costa-Roger, M.; Blasco-Perez, L.; Cusco, I.; Tizzano, E.F. The Importance of Digging into the Genetics of SMN Genes in the Therapeutic Scenario of Spinal Muscular Atrophy. Int. J. Mol. Sci. 2021, 22, 9029. [Google Scholar] [CrossRef]
- Singh, N.N.; O’Leary, C.A.; Eich, T.; Moss, W.N.; Singh, R.N. Structural Context of a Critical Exon of Spinal Muscular Atrophy Gene. Front. Mol. Biosci. 2022, 9, 928581. [Google Scholar] [CrossRef] [PubMed]
- Lorson, C.L.; Strasswimmer, J.; Yao, J.M.; Baleja, J.D.; Hahnen, E.; Wirth, B.; Le, T.; Burghes, A.H.; Androphy, E.J. SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat. Genet. 1998, 19, 63–66. [Google Scholar] [CrossRef] [PubMed]
- Sarachan, K.L.; Valentine, K.G.; Gupta, K.; Moorman, V.R.; Gledhill, J.M., Jr.; Bernens, M.; Tommos, C.; Wand, A.J.; Van Duyne, G.D. Solution structure of the core SMN-Gemin2 complex. Biochem. J. 2012, 445, 361–370. [Google Scholar] [CrossRef]
- Tapia, O.; Lafarga, V.; Bengoechea, R.; Palanca, A.; Lafarga, M.; Berciano, M.T. The SMN Tudor SIM-like domain is key to SmD1 and coilin interactions and to Cajal body biogenesis. J. Cell Sci. 2014, 127, 939–946. [Google Scholar] [CrossRef]
- Selenko, P.; Sprangers, R.; Stier, G.; Buhler, D.; Fischer, U.; Sattler, M. SMN tudor domain structure and its interaction with the Sm proteins. Nat. Struct. Biol. 2001, 8, 27–31. [Google Scholar] [CrossRef]
- Musawi, S.; Donnio, L.M.; Zhao, Z.; Magnani, C.; Rassinoux, P.; Binda, O.; Huang, J.; Jacquier, A.; Coudert, L.; Lomonte, P.; et al. Nucleolar reorganization after cellular stress is orchestrated by SMN shuttling between nuclear compartments. Nat. Commun. 2023, 14, 7384. [Google Scholar] [CrossRef]
- Hebert, M.D.; Szymczyk, P.W.; Shpargel, K.B.; Matera, A.G. Coilin forms the bridge between Cajal bodies and SMN, the spinal muscular atrophy protein. Genes. Dev. 2001, 15, 2720–2729. [Google Scholar] [CrossRef]
- Fortuna, T.R.; Kour, S.; Chimata, A.V.; Muinos-Buhl, A.; Anderson, E.N.; Nelson Iv, C.H.; Ward, C.; Chauhan, O.; O’Brien, C.; Rajasundaram, D.; et al. SMN regulates GEMIN5 expression and acts as a modifier of GEMIN5-mediated neurodegeneration. Acta Neuropathol. 2023, 146, 477–498. [Google Scholar] [CrossRef]
- Binda, O.; Juillard, F.; Ducassou, J.N.; Kleijwegt, C.; Paris, G.; Didillon, A.; Baklouti, F.; Corpet, A.; Coute, Y.; Cote, J.; et al. SMA-linked SMN mutants prevent phase separation properties and SMN interactions with FMRP family members. Life Sci. Alliance 2023, 6, e202201429. [Google Scholar] [CrossRef]
- Pellizzoni, L.; Baccon, J.; Charroux, B.; Dreyfuss, G. The survival of motor neurons (SMN) protein interacts with the snoRNP proteins fibrillarin and GAR1. Curr. Biol. 2001, 11, 1079–1088. [Google Scholar] [CrossRef]
- Adami, R.; Bottai, D. NSC Physiological Features in Spinal Muscular Atrophy: SMN Deficiency Effects on Neurogenesis. Int. J. Mol. Sci. 2022, 23, 15209. [Google Scholar] [CrossRef]
- Detering, N.T.; Schuning, T.; Hensel, N.; Claus, P. The phospho-landscape of the survival of motoneuron protein (SMN) protein: Relevance for spinal muscular atrophy (SMA). Cell. Mol. Life Sci. 2022, 79, 497. [Google Scholar] [CrossRef]
- Singh, R.N.; Howell, M.D.; Ottesen, E.W.; Singh, N.N. Diverse role of survival motor neuron protein. Biochim. Biophys. Acta Gene Regul. Mech. 2017, 1860, 299–315. [Google Scholar] [CrossRef]
- Ji, C.; Bader, J.; Ramanathan, P.; Hennlein, L.; Meissner, F.; Jablonka, S.; Mann, M.; Fischer, U.; Sendtner, M.; Briese, M. Interaction of 7SK with the Smn complex modulates snRNP production. Nat. Commun. 2021, 12, 1278. [Google Scholar] [CrossRef]
- Panek, J.; Roithova, A.; Radivojevic, N.; Sykora, M.; Prusty, A.B.; Huston, N.; Wan, H.; Pyle, A.M.; Fischer, U.; Stanek, D. The SMN complex drives structural changes in human snRNAs to enable snRNP assembly. Nat. Commun. 2023, 14, 6580. [Google Scholar] [CrossRef]
- Tapia, O.; Bengoechea, R.; Palanca, A.; Arteaga, R.; Val-Bernal, J.F.; Tizzano, E.F.; Berciano, M.T.; Lafarga, M. Reorganization of Cajal bodies and nucleolar targeting of coilin in motor neurons of type I spinal muscular atrophy. Histochem. Cell Biol. 2012, 137, 657–667. [Google Scholar] [CrossRef]
- Franco-Espin, J.; Gatius, A.; Armengol, J.A.; Arumugam, S.; Moradi, M.; Sendtner, M.; Caldero, J.; Tabares, L. SMN Is Physiologically Downregulated at Wild-Type Motor Nerve Terminals but Aggregates Together with Neurofilaments in SMA Mouse Models. Biomolecules 2022, 12, 1524. [Google Scholar] [CrossRef]
- Jha, N.N.; Kim, J.K.; Her, Y.R.; Monani, U.R. Muscle: An independent contributor to the neuromuscular spinal muscular atrophy disease phenotype. JCI Insight 2023, 8, e171878. [Google Scholar] [CrossRef]
- Ikenaka, A.; Kitagawa, Y.; Yoshida, M.; Lin, C.Y.; Niwa, A.; Nakahata, T.; Saito, M.K. SMN promotes mitochondrial metabolic maturation during myogenesis by regulating the MYOD-miRNA axis. Life Sci. Alliance 2023, 6, e202201457. [Google Scholar] [CrossRef]
- Sansa, A.; Hidalgo, I.; Miralles, M.P.; de la Fuente, S.; Perez-Garcia, M.J.; Munell, F.; Soler, R.M.; Garcera, A. Spinal Muscular Atrophy autophagy profile is tissue-dependent: Differential regulation between muscle and motoneurons. Acta Neuropathol. Commun. 2021, 9, 122. [Google Scholar] [CrossRef]
- Gavrilina, T.O.; McGovern, V.L.; Workman, E.; Crawford, T.O.; Gogliotti, R.G.; DiDonato, C.J.; Monani, U.R.; Morris, G.E.; Burghes, A.H. Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect. Hum. Mol. Genet. 2008, 17, 1063–1075. [Google Scholar] [CrossRef]
- Arnold, A.S.; Gueye, M.; Guettier-Sigrist, S.; Courdier-Fruh, I.; Coupin, G.; Poindron, P.; Gies, J.P. Reduced expression of nicotinic AChRs in myotubes from spinal muscular atrophy I patients. Lab. Investig. 2004, 84, 1271–1278. [Google Scholar] [CrossRef]
- Bricceno, K.V.; Sampognaro, P.J.; Van Meerbeke, J.P.; Sumner, C.J.; Fischbeck, K.H.; Burnett, B.G. Histone deacetylase inhibition suppresses myogenin-dependent atrogene activation in spinal muscular atrophy mice. Hum. Mol. Genet. 2012, 21, 4448–4459. [Google Scholar] [CrossRef]
- Cifuentes-Diaz, C.; Frugier, T.; Tiziano, F.D.; Lacene, E.; Roblot, N.; Joshi, V.; Moreau, M.H.; Melki, J. Deletion of murine SMN exon 7 directed to skeletal muscle leads to severe muscular dystrophy. J. Cell Biol. 2001, 152, 1107–1114. [Google Scholar] [CrossRef]
- Kim, J.; Won, K.J.; Lee, H.M.; Hwang, B.Y.; Bae, Y.M.; Choi, W.S.; Song, H.; Lim, K.W.; Lee, C.K.; Kim, B. p38 MAPK Participates in Muscle-Specific RING Finger 1-Mediated Atrophy in Cast-Immobilized Rat Gastrocnemius Muscle. Korean J. Physiol. Pharmacol. 2009, 13, 491–496. [Google Scholar] [CrossRef]
- Berciano, M.T.; Castillo-Iglesias, M.S.; Val-Bernal, J.F.; Lafarga, V.; Rodriguez-Rey, J.C.; Lafarga, M.; Tapia, O. Mislocalization of SMN from the I-band and M-band in human skeletal myofibers in spinal muscular atrophy associates with primary structural alterations of the sarcomere. Cell Tissue Res. 2020, 381, 461–478. [Google Scholar] [CrossRef]
- Berciano, M.T.; Puente-Bedia, A.; Medina-Samame, A.; Rodriguez-Rey, J.C.; Caldero, J.; Lafarga, M.; Tapia, O. Nusinersen ameliorates motor function and prevents motoneuron Cajal body disassembly and abnormal poly(A) RNA distribution in a SMA mouse model. Sci. Rep. 2020, 10, 10738. [Google Scholar] [CrossRef]
- Braun, S.; Croizat, B.; Lagrange, M.C.; Poindron, P.; Warter, J.M. Degeneration of cocultures of spinal muscular atrophy muscle cells and rat spinal cord explants is not due to secreted factors and cannot be prevented by neurotrophins. Muscle Nerve 1997, 20, 953–960. [Google Scholar] [CrossRef]
- Braun, S.; Croizat, B.; Lagrange, M.C.; Warter, J.M.; Poindron, P. Constitutive muscular abnormalities in culture in spinal muscular atrophy. Lancet 1995, 345, 694–695. [Google Scholar] [CrossRef]
- Guettier-Sigrist, S.; Hugel, B.; Coupin, G.; Freyssinet, J.M.; Poindron, P.; Warter, J.M. Possible pathogenic role of muscle cell dysfunction in motor neuron death in spinal muscular atrophy. Muscle Nerve 2002, 25, 700–708. [Google Scholar] [CrossRef]
- Martinez-Hernandez, R.; Soler-Botija, C.; Also, E.; Alias, L.; Caselles, L.; Gich, I.; Bernal, S.; Tizzano, E.F. The developmental pattern of myotubes in spinal muscular atrophy indicates prenatal delay of muscle maturation. J. Neuropathol. Exp. Neurol. 2009, 68, 474–481. [Google Scholar] [CrossRef]
- Ikeda, F. Protein and nonprotein targets of ubiquitin modification. Am. J. Physiol. Cell Physiol. 2023, 324, C1053–C1060. [Google Scholar] [CrossRef] [PubMed]
- Goldstein, G.; Scheid, M.; Hammerling, U.; Schlesinger, D.H.; Niall, H.D.; Boyse, E.A. Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells. Proc. Natl. Acad. Sci. USA 1975, 72, 11–15. [Google Scholar] [CrossRef]
- Hunt, L.T.; Dayhoff, M.O. Amino-terminal sequence identity of ubiquitin and the nonhistone component of nuclear protein A24. Biochem. Biophys. Res. Commun. 1977, 74, 650–655. [Google Scholar] [CrossRef]
- Hwang, J.T.; Lee, A.; Kho, C. Ubiquitin and Ubiquitin-like Proteins in Cancer, Neurodegenerative Disorders, and Heart Diseases. Int. J. Mol. Sci. 2022, 23, 5053. [Google Scholar] [CrossRef] [PubMed]
- Damgaard, R.B. The ubiquitin system: From cell signalling to disease biology and new therapeutic opportunities. Cell Death Differ. 2021, 28, 423–426. [Google Scholar] [CrossRef]
- Dikic, I.; Schulman, B.A. An expanded lexicon for the ubiquitin code. Nat. Rev. Mol. Cell Biol. 2023, 24, 273–287. [Google Scholar] [CrossRef] [PubMed]
- Akizuki, Y.; Kaypee, S.; Ohtake, F.; Ikeda, F. The emerging roles of non-canonical ubiquitination in proteostasis and beyond. J. Cell Biol. 2024, 223, e202311171. [Google Scholar] [CrossRef] [PubMed]
- Tracz, M.; Bialek, W. Beyond K48 and K63: Non-canonical protein ubiquitination. Cell Mol. Biol. Lett. 2021, 26, 1. [Google Scholar] [CrossRef] [PubMed]
- Hershko, A.; Heller, H.; Elias, S.; Ciechanover, A. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J. Biol. Chem. 1983, 258, 8206–8214. [Google Scholar] [CrossRef] [PubMed]
- Schulman, B.A.; Harper, J.W. Ubiquitin-like protein activation by E1 enzymes: The apex for downstream signalling pathways. Nat. Rev. Mol. Cell Biol. 2009, 10, 319–331. [Google Scholar] [CrossRef] [PubMed]
- Sherpa, D.; Chrustowicz, J.; Schulman, B.A. How the ends signal the end: Regulation by E3 ubiquitin ligases recognizing protein termini. Mol. Cell 2022, 82, 1424–1438. [Google Scholar] [CrossRef]
- Yang, Q.; Zhao, J.; Chen, D.; Wang, Y. E3 ubiquitin ligases: Styles, structures and functions. Mol. Biomed. 2021, 2, 23. [Google Scholar] [CrossRef]
- Kelsall, I.R. Non-lysine ubiquitylation: Doing things differently. Front. Mol. Biosci. 2022, 9, 1008175. [Google Scholar] [CrossRef]
- Jevtic, P.; Haakonsen, D.L.; Rape, M. An E3 ligase guide to the galaxy of small-molecule-induced protein degradation. Cell Chem. Biol. 2021, 28, 1000–1013. [Google Scholar] [CrossRef]
- Sampson, C.; Wang, Q.; Otkur, W.; Zhao, H.; Lu, Y.; Liu, X.; Piao, H.L. The roles of E3 ubiquitin ligases in cancer progression and targeted therapy. Clin. Transl. Med. 2023, 13, e1204. [Google Scholar] [CrossRef]
- Jeong, Y.; Oh, A.R.; Jung, Y.H.; Gi, H.; Kim, Y.U.; Kim, K. Targeting E3 ubiquitin ligases and their adaptors as a therapeutic strategy for metabolic diseases. Exp. Mol. Med. 2023, 55, 2097–2104. [Google Scholar] [CrossRef]
- Peris-Moreno, D.; Cussonneau, L.; Combaret, L.; Polge, C.; Taillandier, D. Ubiquitin Ligases at the Heart of Skeletal Muscle Atrophy Control. Molecules 2021, 26, 407. [Google Scholar] [CrossRef]
- Hughes, D.C.; Baehr, L.M.; Waddell, D.S.; Sharples, A.P.; Bodine, S.C. Ubiquitin Ligases in Longevity and Aging Skeletal Muscle. Int. J. Mol. Sci. 2022, 23, 7602. [Google Scholar] [CrossRef]
- Huibregtse, J.M.; Scheffner, M.; Beaudenon, S.; Howley, P.M. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc. Natl. Acad. Sci. USA 1995, 92, 5249. [Google Scholar] [CrossRef]
- Weber, J.; Polo, S.; Maspero, E. HECT E3 Ligases: A Tale With Multiple Facets. Front. Physiol. 2019, 10, 370. [Google Scholar] [CrossRef]
- Huang, L.; Kinnucan, E.; Wang, G.; Beaudenon, S.; Howley, P.M.; Huibregtse, J.M.; Pavletich, N.P. Structure of an E6AP-UbcH7 complex: Insights into ubiquitination by the E2-E3 enzyme cascade. Science 1999, 286, 1321–1326. [Google Scholar] [CrossRef]
- Deshaies, R.J.; Joazeiro, C.A. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 2009, 78, 399–434. [Google Scholar] [CrossRef]
- Freemont, P.S.; Hanson, I.M.; Trowsdale, J. A novel cysteine-rich sequence motif. Cell 1991, 64, 483–484. [Google Scholar] [CrossRef]
- Balaji, V.; Hoppe, T. Regulation of E3 ubiquitin ligases by homotypic and heterotypic assembly. F1000Research 2020, 9, 88. [Google Scholar] [CrossRef]
- Brzovic, P.S.; Rajagopal, P.; Hoyt, D.W.; King, M.C.; Klevit, R.E. Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat. Struct. Biol. 2001, 8, 833–837. [Google Scholar] [CrossRef]
- Noy, T.; Suad, O.; Taglicht, D.; Ciechanover, A. HUWE1 ubiquitinates MyoD and targets it for proteasomal degradation. Biochem. Biophys. Res. Commun. 2012, 418, 408–413. [Google Scholar] [CrossRef]
- Sander, B.; Xu, W.; Eilers, M.; Popov, N.; Lorenz, S. A conformational switch regulates the ubiquitin ligase HUWE1. eLife 2017, 6, e21036. [Google Scholar] [CrossRef]
- Harper, J.W.; Schulman, B.A. Cullin-RING Ubiquitin Ligase Regulatory Circuits: A Quarter Century Beyond the F-Box Hypothesis. Annu. Rev. Biochem. 2021, 90, 403–429. [Google Scholar] [CrossRef] [PubMed]
- Aravind, L.; Koonin, E.V. The U box is a modified RING finger—A common domain in ubiquitination. Curr. Biol. 2000, 10, R132–R134. [Google Scholar] [CrossRef]
- Wenzel, D.M.; Lissounov, A.; Brzovic, P.S.; Klevit, R.E. UBCH7 reactivity profile reveals parkin and HHARI to be RING/HECT hybrids. Nature 2011, 474, 105–108. [Google Scholar] [CrossRef]
- Wang, X.S.; Cotton, T.R.; Trevelyan, S.J.; Richardson, L.W.; Lee, W.T.; Silke, J.; Lechtenberg, B.C. The unifying catalytic mechanism of the RING-between-RING E3 ubiquitin ligase family. Nat. Commun. 2023, 14, 168. [Google Scholar] [CrossRef] [PubMed]
- Bodine, S.C.; Latres, E.; Baumhueter, S.; Lai, V.K.; Nunez, L.; Clarke, B.A.; Poueymirou, W.T.; Panaro, F.J.; Na, E.; Dharmarajan, K.; et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001, 294, 1704–1708. [Google Scholar] [CrossRef] [PubMed]
- Peris-Moreno, D.; Taillandier, D.; Polge, C. MuRF1/TRIM63, Master Regulator of Muscle Mass. Int. J. Mol. Sci. 2020, 21, 6663. [Google Scholar] [CrossRef] [PubMed]
- Chen, K.; Gao, P.; Li, Z.; Dai, A.; Yang, M.; Chen, S.; Su, J.; Deng, Z.; Li, L. Forkhead Box O Signaling Pathway in Skeletal Muscle Atrophy. Am. J. Pathol. 2022, 192, 1648–1657. [Google Scholar] [CrossRef] [PubMed]
- O’Neill, B.T.; Bhardwaj, G.; Penniman, C.M.; Krumpoch, M.T.; Suarez Beltran, P.A.; Klaus, K.; Poro, K.; Li, M.; Pan, H.; Dreyfuss, J.M.; et al. FoxO Transcription Factors Are Critical Regulators of Diabetes-Related Muscle Atrophy. Diabetes 2019, 68, 556–570. [Google Scholar] [CrossRef] [PubMed]
- Okada, K.; Naito, A.T.; Higo, T.; Nakagawa, A.; Shibamoto, M.; Sakai, T.; Hashimoto, A.; Kuramoto, Y.; Sumida, T.; Nomura, S.; et al. Wnt/beta-Catenin Signaling Contributes to Skeletal Myopathy in Heart Failure via Direct Interaction with Forkhead Box O. Circ. Heart Fail. 2015, 8, 799–808. [Google Scholar] [CrossRef] [PubMed]
- Zhang, H.; Chi, M.; Chen, L.; Sun, X.; Wan, L.; Yang, Q.; Guo, C. Daidzein alleviates cisplatin-induced muscle atrophy by regulating Glut4/AMPK/FoxO pathway. Phytother. Res. 2021, 35, 4363–4376. [Google Scholar] [CrossRef]
- Adams, V.; Mangner, N.; Gasch, A.; Krohne, C.; Gielen, S.; Hirner, S.; Thierse, H.J.; Witt, C.C.; Linke, A.; Schuler, G.; et al. Induction of MuRF1 is essential for TNF-alpha-induced loss of muscle function in mice. J. Mol. Biol. 2008, 384, 48–59. [Google Scholar] [CrossRef] [PubMed]
- Bollinger, L.M.; Witczak, C.A.; Houmard, J.A.; Brault, J.J. SMAD3 augments FoxO3-induced MuRF-1 promoter activity in a DNA-binding-dependent manner. Am. J. Physiol. Cell Physiol. 2014, 307, C278–C287. [Google Scholar] [CrossRef] [PubMed]
- Sartori, R.; Milan, G.; Patron, M.; Mammucari, C.; Blaauw, B.; Abraham, R.; Sandri, M. Smad2 and 3 transcription factors control muscle mass in adulthood. Am. J. Physiol. Cell Physiol. 2009, 296, C1248–C1257. [Google Scholar] [CrossRef] [PubMed]
- Waddell, D.S.; Baehr, L.M.; van den Brandt, J.; Johnsen, S.A.; Reichardt, H.M.; Furlow, J.D.; Bodine, S.C. The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am. J. Physiol. Endocrinol. Metab. 2008, 295, E785–E797. [Google Scholar] [CrossRef]
- Yamamoto, Y.; Hoshino, Y.; Ito, T.; Nariai, T.; Mohri, T.; Obana, M.; Hayata, N.; Uozumi, Y.; Maeda, M.; Fujio, Y.; et al. Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes. Cardiovasc. Res. 2008, 79, 89–96. [Google Scholar] [CrossRef]
- Editorial, O. Erratum to inhibition of IL-6/JAK/STAT3 pathway rescues denervation-induced skeletal muscle atrophy. Ann. Transl. Med. 2021, 9, 826. [Google Scholar] [CrossRef] [PubMed]
- Oyabu, M.; Takigawa, K.; Mizutani, S.; Hatazawa, Y.; Fujita, M.; Ohira, Y.; Sugimoto, T.; Suzuki, O.; Tsuchiya, K.; Suganami, T.; et al. FOXO1 cooperates with C/EBPdelta and ATF4 to regulate skeletal muscle atrophy transcriptional program during fasting. FASEB J. 2022, 36, e22152. [Google Scholar] [CrossRef]
- Fujimaki, S.; Matsumoto, T.; Muramatsu, M.; Nagahisa, H.; Horii, N.; Seko, D.; Masuda, S.; Wang, X.; Asakura, Y.; Takahashi, Y.; et al. The endothelial Dll4-muscular Notch2 axis regulates skeletal muscle mass. Nat. Metab. 2022, 4, 180–189. [Google Scholar] [CrossRef] [PubMed]
- Reed, S.A.; Senf, S.M.; Cornwell, E.W.; Kandarian, S.C.; Judge, A.R. Inhibition of IkappaB kinase alpha (IKKalpha) or IKKbeta (IKKbeta) plus forkhead box O (Foxo) abolishes skeletal muscle atrophy. Biochem. Biophys. Res. Commun. 2011, 405, 491–496. [Google Scholar] [CrossRef] [PubMed]
- Cai, D.; Frantz, J.D.; Tawa, N.E., Jr.; Melendez, P.A.; Oh, B.C.; Lidov, H.G.; Hasselgren, P.O.; Frontera, W.R.; Lee, J.; Glass, D.J.; et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004, 119, 285–298. [Google Scholar] [CrossRef] [PubMed]
- Baehr, L.M.; Hughes, D.C.; Lynch, S.A.; Van Haver, D.; Maia, T.M.; Marshall, A.G.; Radoshevich, L.; Impens, F.; Waddell, D.S.; Bodine, S.C. Identification of the MuRF1 Skeletal Muscle Ubiquitylome through Quantitative Proteomics. Function 2021, 2, zqab029. [Google Scholar] [CrossRef] [PubMed]
- Peris-Moreno, D.; Malige, M.; Claustre, A.; Armani, A.; Coudy-Gandilhon, C.; Deval, C.; Bechet, D.; Fafournoux, P.; Sandri, M.; Combaret, L.; et al. UBE2L3, a Partner of MuRF1/TRIM63, Is Involved in the Degradation of Myofibrillar Actin and Myosin. Cells 2021, 10, 1974. [Google Scholar] [CrossRef] [PubMed]
- Clarke, B.A.; Drujan, D.; Willis, M.S.; Murphy, L.O.; Corpina, R.A.; Burova, E.; Rakhilin, S.V.; Stitt, T.N.; Patterson, C.; Latres, E.; et al. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 2007, 6, 376–385. [Google Scholar] [CrossRef] [PubMed]
- Polge, C.; Heng, A.E.; Jarzaguet, M.; Ventadour, S.; Claustre, A.; Combaret, L.; Bechet, D.; Matondo, M.; Uttenweiler-Joseph, S.; Monsarrat, B.; et al. Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1. FASEB J. 2011, 25, 3790–3802. [Google Scholar] [CrossRef]
- Kedar, V.; McDonough, H.; Arya, R.; Li, H.H.; Rockman, H.A.; Patterson, C. Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc. Natl. Acad. Sci. USA 2004, 101, 18135–18140. [Google Scholar] [CrossRef]
- McElhinny, A.S.; Kakinuma, K.; Sorimachi, H.; Labeit, S.; Gregorio, C.C. Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1. J. Cell Biol. 2002, 157, 125–136. [Google Scholar] [CrossRef]
- Labeit, S.; Hirner, S.; Bogomolovas, J.; Cruz, A.; Myrzabekova, M.; Moriscot, A.; Bowen, T.S.; Adams, V. Regulation of Glucose Metabolism by MuRF1 and Treatment of Myopathy in Diabetic Mice with Small Molecules Targeting MuRF1. Int. J. Mol. Sci. 2021, 22, 2225. [Google Scholar] [CrossRef]
- Uenaka, E.; Ojima, K.; Suzuki, T.; Kobayashi, K.; Muroya, S.; Nishimura, T. Murf1 alters myosin replacement rates in cultured myotubes in a myosin isoform-dependent manner. In Vitro Cell. Dev. Biol. Anim. 2024, 60, 748–759. [Google Scholar] [CrossRef] [PubMed]
- Lokireddy, S.; Wijesoma, I.W.; Sze, S.K.; McFarlane, C.; Kambadur, R.; Sharma, M. Identification of atrogin-1-targeted proteins during the myostatin-induced skeletal muscle wasting. Am. J. Physiol. Cell Physiol. 2012, 303, C512–C529. [Google Scholar] [CrossRef] [PubMed]
- Lagirand-Cantaloube, J.; Offner, N.; Csibi, A.; Leibovitch, M.P.; Batonnet-Pichon, S.; Tintignac, L.A.; Segura, C.T.; Leibovitch, S.A. The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy. EMBO J. 2008, 27, 1266–1276. [Google Scholar] [CrossRef]
- Chung, S.W.; Kim, J.Y.; Yoon, J.P.; Suh, D.W.; Yeo, W.J.; Lee, Y.S. Atrogin1-induced loss of aquaporin 4 in myocytes leads to skeletal muscle atrophy. Sci. Rep. 2020, 10, 14189. [Google Scholar] [CrossRef]
- Ruparelia, A.A.; Montandon, M.; Merriner, J.; Huang, C.; Wong, S.F.L.; Sonntag, C.; Hardee, J.P.; Lynch, G.S.; Miles, L.B.; Siegel, A.; et al. Atrogin-1 promotes muscle homeostasis by regulating levels of endoplasmic reticulum chaperone BiP. JCI Insight 2024, 9, e167578. [Google Scholar] [CrossRef]
- Boido, M.; Gesmundo, I.; Caretto, A.; Pedrolli, F.; Schellino, R.; Leone, S.; Cai, R.; Sha, W.; Ghigo, E.; Schally, A.V.; et al. Agonist of growth hormone-releasing hormone improves the disease features of spinal muscular atrophy mice. Proc. Natl. Acad. Sci. USA 2023, 120, e2216814120. [Google Scholar] [CrossRef] [PubMed]
- Iyer, C.C.; McGovern, V.L.; Wise, D.O.; Glass, D.J.; Burghes, A.H. Deletion of atrophy enhancing genes fails to ameliorate the phenotype in a mouse model of spinal muscular atrophy. Neuromuscul. Disord. 2014, 24, 436–444. [Google Scholar] [CrossRef]
- Milan, G.; Romanello, V.; Pescatore, F.; Armani, A.; Paik, J.H.; Frasson, L.; Seydel, A.; Zhao, J.; Abraham, R.; Goldberg, A.L.; et al. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. Nat. Commun. 2015, 6, 6670. [Google Scholar] [CrossRef]
- Yang, L.; Jiang, X.; Fu, S.; Tan, J.; Dian, W.; Zhou, Y. IGF-1 Regulates Skeletal Muscle Degradation and Remolding in Ventilator-Induced Diaphragmatic Dysfunction by Mediating FOXO1 Expression. Discov. Med. 2024, 36, 402–414. [Google Scholar] [CrossRef]
- Hughes, D.C.; Goodman, C.A.; Baehr, L.M.; Gregorevic, P.; Bodine, S.C. A critical discussion on the relationship between E3 ubiquitin ligases, protein degradation, and skeletal muscle wasting: It’s not that simple. Am. J. Physiol. Cell Physiol. 2023, 325, C1567–C1582. [Google Scholar] [CrossRef]
- Penniman, C.M.; Bhardwaj, G.; Nowers, C.J.; Brown, C.U.; Junck, T.L.; Boyer, C.K.; Jena, J.; Fuqua, J.D.; Lira, V.A.; O’Neill, B.T. Loss of FoxOs in muscle increases strength and mitochondrial function during aging. J. Cachexia Sarcopenia Muscle 2023, 14, 243–259. [Google Scholar] [CrossRef]
- Hughes, D.C.; Baehr, L.M.; Driscoll, J.R.; Lynch, S.A.; Waddell, D.S.; Bodine, S.C. Identification and characterization of Fbxl22, a novel skeletal muscle atrophy-promoting E3 ubiquitin ligase. Am. J. Physiol. Cell Physiol. 2020, 319, C700–C719. [Google Scholar] [CrossRef]
- An, C.I.; Ganio, E.; Hagiwara, N. Trip12, a HECT domain E3 ubiquitin ligase, targets Sox6 for proteasomal degradation and affects fiber type-specific gene expression in muscle cells. Skelet. Muscle 2013, 3, 11. [Google Scholar] [CrossRef]
- Ciciliot, S.; Rossi, A.C.; Dyar, K.A.; Blaauw, B.; Schiaffino, S. Muscle type and fiber type specificity in muscle wasting. Int. J. Biochem. Cell Biol. 2013, 45, 2191–2199. [Google Scholar] [CrossRef]
- Cai, S.C.; Yi, C.A.; Hu, X.S.; Tang, G.Y.; Yi, L.M.; Li, X.P. Isoquercitrin Upregulates Aldolase C Through Nrf2 to Ameliorate OGD/R-Induced Damage in SH-SY5Y Cells. Neurotox. Res. 2021, 39, 1959–1969. [Google Scholar] [CrossRef]
- Shen, Y.; Zhang, Q.; Huang, Z.; Zhu, J.; Qiu, J.; Ma, W.; Yang, X.; Ding, F.; Sun, H. Isoquercitrin Delays Denervated Soleus Muscle Atrophy by Inhibiting Oxidative Stress and Inflammation. Front. Physiol. 2020, 11, 988. [Google Scholar] [CrossRef]
- Gomez-Garcia, E.F.; Del Campo, F.M.; Cortes-Sanabria, L.; Mendoza-Carrera, F.; Avesani, C.M.; Stenvinkel, P.; Lindholm, B.; Cueto-Manzano, A.M. Transcription factor NRF2 as potential therapeutic target for preventing muscle wasting in aging chronic kidney disease patients. J. Nephrol. 2022, 35, 2215–2225. [Google Scholar] [CrossRef]
- Ripolone, M.; Ronchi, D.; Violano, R.; Vallejo, D.; Fagiolari, G.; Barca, E.; Lucchini, V.; Colombo, I.; Villa, L.; Berardinelli, A.; et al. Impaired Muscle Mitochondrial Biogenesis and Myogenesis in Spinal Muscular Atrophy. JAMA Neurol. 2015, 72, 666–675. [Google Scholar] [CrossRef]
- Yoshida, T.; Delafontaine, P. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells 2020, 9, 1970. [Google Scholar] [CrossRef] [PubMed]
- Sansa, A.; de la Fuente, S.; Comella, J.X.; Garcera, A.; Soler, R.M. Intracellular pathways involved in cell survival are deregulated in mouse and human spinal muscular atrophy motoneurons. Neurobiol. Dis. 2021, 155, 105366. [Google Scholar] [CrossRef]
- Sansa, A.; Miralles, M.P.; Beltran, M.; Celma-Nos, F.; Caldero, J.; Garcera, A.; Soler, R.M. ERK MAPK signaling pathway inhibition as a potential target to prevent autophagy alterations in Spinal Muscular Atrophy motoneurons. Cell Death Discov. 2023, 9, 113. [Google Scholar] [CrossRef]
- Branchu, J.; Biondi, O.; Chali, F.; Collin, T.; Leroy, F.; Mamchaoui, K.; Makoukji, J.; Pariset, C.; Lopes, P.; Massaad, C.; et al. Shift from extracellular signal-regulated kinase to AKT/cAMP response element-binding protein pathway increases survival-motor-neuron expression in spinal-muscular-atrophy-like mice and patient cells. J. Neurosci. 2013, 33, 4280–4294. [Google Scholar] [CrossRef]
- Gandhi, G.; Kodiappan, R.; Abdullah, S.; Teoh, H.K.; Tai, L.; Cheong, S.K.; Yeo, W.W.Y. Revealing the potential role of hsa-miR-663a in modulating the PI3K-Akt signaling pathway via miRNA microarray in spinal muscular atrophy patient fibroblast-derived iPSCs. J. Neuropathol. Exp. Neurol. 2024, nlae065. [Google Scholar] [CrossRef]
- Cohen, S.; Lee, D.; Zhai, B.; Gygi, S.P.; Goldberg, A.L. Trim32 reduces PI3K-Akt-FoxO signaling in muscle atrophy by promoting plakoglobin-PI3K dissociation. J. Cell Biol. 2014, 204, 747–758. [Google Scholar] [CrossRef]
- Jeong, S.Y.; Choi, J.H.; Kim, J.; Woo, J.S.; Lee, E.H. Tripartite Motif-Containing Protein 32 (TRIM32): What Does It Do for Skeletal Muscle? Cells 2023, 12, 2104. [Google Scholar] [CrossRef]
- Kudryashova, E.; Wu, J.; Havton, L.A.; Spencer, M.J. Deficiency of the E3 ubiquitin ligase TRIM32 in mice leads to a myopathy with a neurogenic component. Hum. Mol. Genet. 2009, 18, 1353–1367. [Google Scholar] [CrossRef]
- Servian-Morilla, E.; Cabrera-Serrano, M.; Rivas-Infante, E.; Carvajal, A.; Lamont, P.J.; Pelayo-Negro, A.L.; Ravenscroft, G.; Junckerstorff, R.; Dyke, J.M.; Fletcher, S.; et al. Altered myogenesis and premature senescence underlie human TRIM32-related myopathy. Acta Neuropathol. Commun. 2019, 7, 30. [Google Scholar] [CrossRef]
- Bawa, S.; Piccirillo, R.; Geisbrecht, E.R. TRIM32: A Multifunctional Protein Involved in Muscle Homeostasis, Glucose Metabolism, and Tumorigenesis. Biomolecules 2021, 11, 408. [Google Scholar] [CrossRef]
- Cohen, S.; Zhai, B.; Gygi, S.P.; Goldberg, A.L. Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy. J. Cell Biol. 2012, 198, 575–589. [Google Scholar] [CrossRef]
- Di Rienzo, M.; Antonioli, M.; Fusco, C.; Liu, Y.; Mari, M.; Orhon, I.; Refolo, G.; Germani, F.; Corazzari, M.; Romagnoli, A.; et al. Autophagy induction in atrophic muscle cells requires ULK1 activation by TRIM32 through unanchored K63-linked polyubiquitin chains. Sci. Adv. 2019, 5, eaau8857. [Google Scholar] [CrossRef]
- Overa, K.S.; Garcia-Garcia, J.; Bhujabal, Z.; Jain, A.; Overvatn, A.; Larsen, K.B.; Deretic, V.; Johansen, T.; Lamark, T.; Sjottem, E. TRIM32, but not its muscular dystrophy-associated mutant, positively regulates and is targeted to autophagic degradation by p62/SQSTM1. J. Cell Sci. 2019, 132, jcs.236596. [Google Scholar] [CrossRef]
- Duan, S.; Moro, L.; Qu, R.; Simoneschi, D.; Cho, H.; Jiang, S.; Zhao, H.; Chang, Q.; de Stanchina, E.; Arbini, A.A.; et al. Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesis. Cell Rep. 2021, 37, 109870. [Google Scholar] [CrossRef]
- Vo, A.H.; Swaggart, K.A.; Woo, A.; Gao, Q.Q.; Demonbreun, A.R.; Fallon, K.S.; Quattrocelli, M.; Hadhazy, M.; Page, P.G.T.; Chen, Z.; et al. Dusp6 is a genetic modifier of growth through enhanced ERK activity. Hum. Mol. Genet. 2019, 28, 279–289. [Google Scholar] [CrossRef]
- Choppara, S.; Malonia, S.K.; Sankaran, G.; Green, M.R.; Santra, M.K. Degradation of FBXO31 by APC/C is regulated by AKT- and ATM-mediated phosphorylation. Proc. Natl. Acad. Sci. USA 2018, 115, 998–1003. [Google Scholar] [CrossRef]
- Liu, K.; Xue, B.; Bai, G.; Zhang, W. F-box protein FBXO31 modulates apoptosis and epithelial-mesenchymal transition of cervical cancer via inactivation of the PI3K/AKT-mediated MDM2/p53 axis. Life Sci. 2020, 259, 118277. [Google Scholar] [CrossRef]
- Huang, H.; Tindall, D.J. Regulation of FOXO protein stability via ubiquitination and proteasome degradation. Biochim. Biophys. Acta 2011, 1813, 1961–1964. [Google Scholar] [CrossRef] [PubMed]
- Cai, Q.; Sahu, R.; Ueberschlag-Pitiot, V.; Souali-Crespo, S.; Charvet, C.; Silem, I.; Cottard, F.; Ye, T.; Taleb, F.; Metzger, E.; et al. LSD1 inhibition circumvents glucocorticoid-induced muscle wasting of male mice. Nat. Commun. 2024, 15, 3563. [Google Scholar] [CrossRef]
- He, H.; Dai, J.; Feng, J.; He, Q.; Chen, X.; Dai, W.; Xu, A.; Huang, H. FBXO31 modulates activation of hepatic stellate cells and liver fibrogenesis by promoting ubiquitination of Smad7. J. Cell Biochem. 2020, 121, 3711–3719. [Google Scholar] [CrossRef]
- Zhu, X.; Topouzis, S.; Liang, L.F.; Stotish, R.L. Myostatin signaling through Smad2, Smad3 and Smad4 is regulated by the inhibitory Smad7 by a negative feedback mechanism. Cytokine 2004, 26, 262–272. [Google Scholar] [CrossRef] [PubMed]
- Barrett, D.; Bilic, S.; Chyung, Y.; Cote, S.M.; Iarrobino, R.; Kacena, K.; Kalra, A.; Long, K.; Nomikos, G.; Place, A.; et al. A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy. Adv. Ther. 2021, 38, 3203–3222. [Google Scholar] [CrossRef] [PubMed]
- Long, K.K.; O’Shea, K.M.; Khairallah, R.J.; Howell, K.; Paushkin, S.; Chen, K.S.; Cote, S.M.; Webster, M.T.; Stains, J.P.; Treece, E.; et al. Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy. Hum. Mol. Genet. 2019, 28, 1076–1089. [Google Scholar] [CrossRef] [PubMed]
- Borok, M.J.; Mademtzoglou, D.; Relaix, F. Bu-M-P-ing Iron: How BMP Signaling Regulates Muscle Growth and Regeneration. J. Dev. Biol. 2020, 8, 4. [Google Scholar] [CrossRef]
- Sartori, R.; Schirwis, E.; Blaauw, B.; Bortolanza, S.; Zhao, J.; Enzo, E.; Stantzou, A.; Mouisel, E.; Toniolo, L.; Ferry, A.; et al. BMP signaling controls muscle mass. Nat. Genet. 2013, 45, 1309–1318. [Google Scholar] [CrossRef] [PubMed]
- Sartori, R.; Hagg, A.; Zampieri, S.; Armani, A.; Winbanks, C.E.; Viana, L.R.; Haidar, M.; Watt, K.I.; Qian, H.; Pezzini, C.; et al. Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia. Sci. Transl. Med. 2021, 13, eaay9592. [Google Scholar] [CrossRef]
- Chang, H.C.; Dimlich, D.N.; Yokokura, T.; Mukherjee, A.; Kankel, M.W.; Sen, A.; Sridhar, V.; Fulga, T.A.; Hart, A.C.; Van Vactor, D.; et al. Modeling spinal muscular atrophy in Drosophila. PLoS ONE 2008, 3, e3209. [Google Scholar] [CrossRef] [PubMed]
- Seaborne, R.A.; Hughes, D.C.; Turner, D.C.; Owens, D.J.; Baehr, L.M.; Gorski, P.; Semenova, E.A.; Borisov, O.V.; Larin, A.K.; Popov, D.V.; et al. UBR5 is a novel E3 ubiquitin ligase involved in skeletal muscle hypertrophy and recovery from atrophy. J. Physiol. 2019, 597, 3727–3749. [Google Scholar] [CrossRef] [PubMed]
- Gu, Y.F.; Ge, X.P. UBR5 inhibits the radiosensitivity of non-small cell lung cancer cells via the activation of the PI3K/AKT pathway. J. Investig. Med. 2021, 69, 970–975. [Google Scholar] [CrossRef]
- Saurabh, K.; Shah, P.P.; Doll, M.A.; Siskind, L.J.; Beverly, L.J. UBR-box containing protein, UBR5, is over-expressed in human lung adenocarcinoma and is a potential therapeutic target. BMC Cancer 2020, 20, 824. [Google Scholar] [CrossRef]
- Hughes, D.C.; Turner, D.C.; Baehr, L.M.; Seaborne, R.A.; Viggars, M.; Jarvis, J.C.; Gorski, P.P.; Stewart, C.E.; Owens, D.J.; Bodine, S.C.; et al. Knockdown of the E3 ubiquitin ligase UBR5 and its role in skeletal muscle anabolism. Am. J. Physiol. Cell Physiol. 2021, 320, C45–C56. [Google Scholar] [CrossRef]
- Belova, S.P.; Vilchinskaya, N.A.; Mochalova, E.P.; Mirzoev, T.M.; Nemirovskaya, T.L.; Shenkman, B.S. Elevated p70S6K phosphorylation in rat soleus muscle during the early stage of unloading: Causes and consequences. Arch. Biochem. Biophys. 2019, 674, 108105. [Google Scholar] [CrossRef]
- Sanchez, A.M.; Candau, R.B.; Bernardi, H. FoxO transcription factors: Their roles in the maintenance of skeletal muscle homeostasis. Cell. Mol. Life Sci. 2014, 71, 1657–1671. [Google Scholar] [CrossRef]
- Liu, W.; Li, Y.; Luo, B. Current perspective on the regulation of FOXO4 and its role in disease progression. Cell. Mol. Life Sci. 2020, 77, 651–663. [Google Scholar] [CrossRef]
- Zhang, L.; Zhang, Y.; Zhou, M.; Wang, S.; Li, T.; Hu, Z.; Jin, C. Role and mechanism underlying FoxO6 in skeletal muscle in vitro and in vivo. Int. J. Mol. Med. 2021, 48, 143. [Google Scholar] [CrossRef]
- Cheng, Z. The FoxO-Autophagy Axis in Health and Disease. Trends Endocrinol. Metab. 2019, 30, 658–671. [Google Scholar] [CrossRef]
- Rodriguez-Colman, M.J.; Dansen, T.B.; Burgering, B.M.T. FOXO transcription factors as mediators of stress adaptation. Nat. Rev. Mol. Cell Biol. 2024, 25, 46–64. [Google Scholar] [CrossRef]
- Brocca, L.; Toniolo, L.; Reggiani, C.; Bottinelli, R.; Sandri, M.; Pellegrino, M.A. FoxO-dependent atrogenes vary among catabolic conditions and play a key role in muscle atrophy induced by hindlimb suspension. J. Physiol. 2017, 595, 1143–1158. [Google Scholar] [CrossRef]
- Thrower, J.S.; Hoffman, L.; Rechsteiner, M.; Pickart, C.M. Recognition of the polyubiquitin proteolytic signal. EMBO J. 2000, 19, 94–102. [Google Scholar] [CrossRef] [PubMed]
- Li, N.; Zhao, Z.; Liu, P.; Zheng, Y.; Cai, S.; Sun, Y.; Wang, B. Upregulation of deubiquitinase USP7 by transcription factor FOXO6 promotes EC progression via targeting the JMJD3/CLU axis. Mol. Ther. Oncolytics 2021, 20, 583–595. [Google Scholar] [CrossRef] [PubMed]
- Obsilova, V.; Vecer, J.; Herman, P.; Pabianova, A.; Sulc, M.; Teisinger, J.; Boura, E.; Obsil, T. 14-3-3 Protein interacts with nuclear localization sequence of forkhead transcription factor FoxO4. Biochemistry 2005, 44, 11608–11617. [Google Scholar] [CrossRef]
- Essers, M.A.; de Vries-Smits, L.M.; Barker, N.; Polderman, P.E.; Burgering, B.M.; Korswagen, H.C. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 2005, 308, 1181–1184. [Google Scholar] [CrossRef]
- Zamudio, A.V.; Dall’Agnese, A.; Henninger, J.E.; Manteiga, J.C.; Afeyan, L.K.; Hannett, N.M.; Coffey, E.L.; Li, C.H.; Oksuz, O.; Sabari, B.R.; et al. Mediator Condensates Localize Signaling Factors to Key Cell Identity Genes. Mol. Cell 2019, 76, 753–766.e6. [Google Scholar] [CrossRef]
- Bourgeois, B.; Gui, T.; Hoogeboom, D.; Hocking, H.G.; Richter, G.; Spreitzer, E.; Viertler, M.; Richter, K.; Madl, T.; Burgering, B.M.T. Multiple regulatory intrinsically disordered motifs control FOXO4 transcription factor binding and function. Cell Rep. 2021, 36, 109446. [Google Scholar] [CrossRef]
- Wishart, T.M.; Mutsaers, C.A.; Riessland, M.; Reimer, M.M.; Hunter, G.; Hannam, M.L.; Eaton, S.L.; Fuller, H.R.; Roche, S.L.; Somers, E.; et al. Dysregulation of ubiquitin homeostasis and beta-catenin signaling promote spinal muscular atrophy. J. Clin. Investig. 2014, 124, 1821–1834. [Google Scholar] [CrossRef]
- Kajabadi, N.; Low, M.; Jacques, E.; Lad, H.; Tung, L.W.; Babaeijandaghi, F.; Gamu, D.; Zelada, D.; Wong, C.K.; Chang, C.; et al. Activation of beta-catenin in mesenchymal progenitors leads to muscle mass loss. Dev. Cell 2023, 58, 489–505.e7. [Google Scholar] [CrossRef]
- Liu, Y.; Sun, Y.; Huang, Y.; Cheng, K.; Xu, Y.; Tian, Q.; Zhang, S. CHIP promotes Wnt signaling and regulates Arc stability by recruiting and polyubiquitinating LEF1 or Arc. Cell Death Discov. 2021, 7, 5. [Google Scholar] [CrossRef]
- Ramakrishna, K.; Nalla, L.V.; Naresh, D.; Venkateswarlu, K.; Viswanadh, M.K.; Nalluri, B.N.; Chakravarthy, G.; Duguluri, S.; Singh, P.; Rai, S.N.; et al. WNT-beta Catenin Signaling as a Potential Therapeutic Target for Neurodegenerative Diseases: Current Status and Future Perspective. Diseases 2023, 11, 89. [Google Scholar] [CrossRef] [PubMed]
- Min, J.N.; Whaley, R.A.; Sharpless, N.E.; Lockyer, P.; Portbury, A.L.; Patterson, C. CHIP deficiency decreases longevity, with accelerated aging phenotypes accompanied by altered protein quality control. Mol. Cell. Biol. 2008, 28, 4018–4025. [Google Scholar] [CrossRef] [PubMed]
- Yan, Y.; Li, M.; Lin, J.; Ji, Y.; Wang, K.; Yan, D.; Shen, Y.; Wang, W.; Huang, Z.; Jiang, H.; et al. Adenosine monophosphate activated protein kinase contributes to skeletal muscle health through the control of mitochondrial function. Front. Pharmacol. 2022, 13, 947387. [Google Scholar] [CrossRef] [PubMed]
- Jaitovich, A.; Angulo, M.; Lecuona, E.; Dada, L.A.; Welch, L.C.; Cheng, Y.; Gusarova, G.; Ceco, E.; Liu, C.; Shigemura, M.; et al. High CO2 levels cause skeletal muscle atrophy via AMP-activated kinase (AMPK), FoxO3a protein, and muscle-specific Ring finger protein 1 (MuRF1). J. Biol. Chem. 2015, 290, 9183–9194. [Google Scholar] [CrossRef] [PubMed]
- Jiang, P.; Ren, L.; Zhi, L.; Yu, Z.; Lv, F.; Xu, F.; Peng, W.; Bai, X.; Cheng, K.; Quan, L.; et al. Negative regulation of AMPK signaling by high glucose via E3 ubiquitin ligase MG53. Mol. Cell 2021, 81, 629–637.e5. [Google Scholar] [CrossRef]
- Lijie, G.; Yueyue, Z.; Nan, Z.; Ling, W.; Xuan, W.; Weijie, Y. Mitsugumin 53 promotes mitochondrial autophagy through regulating Ambra1 expression in C2C12 myoblast cells. Cell Biol. Int. 2019, 43, 290–298. [Google Scholar] [CrossRef]
- Chemello, F.; Pozzobon, M.; Tsansizi, L.I.; Varanita, T.; Quintana-Cabrera, R.; Bonesso, D.; Piccoli, M.; Lanfranchi, G.; Giacomello, M.; Scorrano, L.; et al. Dysfunctional mitochondria accumulate in a skeletal muscle knockout model of Smn1, the causal gene of spinal muscular atrophy. Cell Death Dis. 2023, 14, 162. [Google Scholar] [CrossRef] [PubMed]
- Habets, L.E.; Bartels, B.; Asselman, F.L.; Hooijmans, M.T.; van den Berg, S.; Nederveen, A.J.; van der Pol, W.L.; Jeneson, J.A.L. Magnetic resonance reveals mitochondrial dysfunction and muscle remodelling in spinal muscular atrophy. Brain 2022, 145, 1422–1435. [Google Scholar] [CrossRef]
- Cervero, C.; Montull, N.; Tarabal, O.; Piedrafita, L.; Esquerda, J.E.; Caldero, J. Chronic Treatment with the AMPK Agonist AICAR Prevents Skeletal Muscle Pathology but Fails to Improve Clinical Outcome in a Mouse Model of Severe Spinal Muscular Atrophy. Neurotherapeutics 2016, 13, 198–216. [Google Scholar] [CrossRef]
- Cannavino, J.; Brocca, L.; Sandri, M.; Grassi, B.; Bottinelli, R.; Pellegrino, M.A. The role of alterations in mitochondrial dynamics and PGC-1alpha over-expression in fast muscle atrophy following hindlimb unloading. J. Physiol. 2015, 593, 1981–1995. [Google Scholar] [CrossRef]
- Leduc-Gaudet, J.P.; Reynaud, O.; Hussain, S.N.; Gouspillou, G. Parkin overexpression protects from ageing-related loss of muscle mass and strength. J. Physiol. 2019, 597, 1975–1991. [Google Scholar] [CrossRef] [PubMed]
- Peker, N.; Donipadi, V.; Sharma, M.; McFarlane, C.; Kambadur, R. Loss of Parkin impairs mitochondrial function and leads to muscle atrophy. Am. J. Physiol. Cell Physiol. 2018, 315, C164–C185. [Google Scholar] [CrossRef]
- Peker, N.; Sharma, M.; Kambadur, R. Parkin deficiency exacerbates fasting-induced skeletal muscle wasting in mice. NPJ Parkinsons Dis. 2022, 8, 159. [Google Scholar] [CrossRef]
- Esteca, M.V.; Severino, M.B.; Silvestre, J.G.; Palmeira Dos Santos, G.; Tamborlin, L.; Luchessi, A.D.; Moriscot, A.S.; Gustafsson, A.B.; Baptista, I.L. Loss of Parkin Results in Altered Muscle Stem Cell Differentiation during Regeneration. Int. J. Mol. Sci. 2020, 21, 8007. [Google Scholar] [CrossRef]
- Hung, C.M.; Lombardo, P.S.; Malik, N.; Brun, S.N.; Hellberg, K.; Van Nostrand, J.L.; Garcia, D.; Baumgart, J.; Diffenderfer, K.; Asara, J.M.; et al. AMPK/ULK1-mediated phosphorylation of Parkin ACT domain mediates an early step in mitophagy. Sci. Adv. 2021, 7, eabg4544. [Google Scholar] [CrossRef]
- Chang, H.C.; Hung, W.C.; Chuang, Y.J.; Jong, Y.J. Degradation of survival motor neuron (SMN) protein is mediated via the ubiquitin/proteasome pathway. Neurochem. Int. 2004, 45, 1107–1112. [Google Scholar] [CrossRef]
- Gray, K.M.; Kaifer, K.A.; Baillat, D.; Wen, Y.; Bonacci, T.R.; Ebert, A.D.; Raimer, A.C.; Spring, A.M.; Have, S.T.; Glascock, J.J.; et al. Self-oligomerization regulates stability of survival motor neuron protein isoforms by sequestering an SCF(Slmb) degron. Mol. Biol. Cell 2018, 29, 96–110. [Google Scholar] [CrossRef]
- Burnett, B.G.; Munoz, E.; Tandon, A.; Kwon, D.Y.; Sumner, C.J.; Fischbeck, K.H. Regulation of SMN protein stability. Mol. Cell. Biol. 2009, 29, 1107–1115. [Google Scholar] [CrossRef]
- Han, K.J.; Foster, D.G.; Zhang, N.Y.; Kanisha, K.; Dzieciatkowska, M.; Sclafani, R.A.; Hansen, K.C.; Peng, J.; Liu, C.W. Ubiquitin-specific protease 9x deubiquitinates and stabilizes the spinal muscular atrophy protein-survival motor neuron. J. Biol. Chem. 2012, 287, 43741–43752. [Google Scholar] [CrossRef]
- Kwon, D.Y.; Dimitriadi, M.; Terzic, B.; Cable, C.; Hart, A.C.; Chitnis, A.; Fischbeck, K.H.; Burnett, B.G. The E3 ubiquitin ligase mind bomb 1 ubiquitinates and promotes the degradation of survival of motor neuron protein. Mol. Biol. Cell 2013, 24, 1863–1871. [Google Scholar] [CrossRef]
- McCormack, N.M.; Abera, M.B.; Arnold, E.S.; Gibbs, R.M.; Martin, S.E.; Buehler, E.; Chen, Y.C.; Chen, L.; Fischbeck, K.H.; Burnett, B.G. A high-throughput genome-wide RNAi screen identifies modifiers of survival motor neuron protein. Cell Rep. 2021, 35, 109125. [Google Scholar] [CrossRef]
- Hsu, S.H.; Lai, M.C.; Er, T.K.; Yang, S.N.; Hung, C.H.; Tsai, H.H.; Lin, Y.C.; Chang, J.G.; Lo, Y.C.; Jong, Y.J. Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) regulates the level of SMN expression through ubiquitination in primary spinal muscular atrophy fibroblasts. Clin. Chim. Acta 2010, 411, 1920–1928. [Google Scholar] [CrossRef]
- Fuller, H.R.; Mandefro, B.; Shirran, S.L.; Gross, A.R.; Kaus, A.S.; Botting, C.H.; Morris, G.E.; Sareen, D. Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Have Reduced Expression of Proteins Important in Neuronal Development. Front. Cell. Neurosci. 2015, 9, 506. [Google Scholar] [CrossRef]
- Powis, R.A.; Mutsaers, C.A.; Wishart, T.M.; Hunter, G.; Wirth, B.; Gillingwater, T.H. Increased levels of UCHL1 are a compensatory response to disrupted ubiquitin homeostasis in spinal muscular atrophy and do not represent a viable therapeutic target. Neuropathol. Appl. Neurobiol. 2014, 40, 873–887. [Google Scholar] [CrossRef] [PubMed]
- Han, K.J.; Foster, D.; Harhaj, E.W.; Dzieciatkowska, M.; Hansen, K.; Liu, C.W. Monoubiquitination of survival motor neuron regulates its cellular localization and Cajal body integrity. Hum. Mol. Genet. 2016, 25, 1392–1405. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Chen, X.; Wang, Q.; Du, C.; Lu, W.; Yuan, H.; Zhang, Z.; Li, D.; Ling, X.; Ren, X.; et al. Hyper-SUMOylation of SMN induced by SENP2 deficiency decreases its stability and leads to spinal muscular atrophy-like pathology. J. Mol. Med. 2021, 99, 1797–1813. [Google Scholar] [CrossRef] [PubMed]
- Goto, J.; Otaki, Y.; Watanabe, T.; Kobayashi, Y.; Aono, T.; Watanabe, K.; Wanezaki, M.; Kutsuzawa, D.; Kato, S.; Tamura, H.; et al. HECT (Homologous to the E6-AP Carboxyl Terminus)-Type Ubiquitin E3 Ligase ITCH Attenuates Cardiac Hypertrophy by Suppressing the Wnt/beta-Catenin Signaling Pathway. Hypertension 2020, 76, 1868–1878. [Google Scholar] [CrossRef]
- Wolfe, R.; Heiman, P.; D’Annibale, O.; Karunanidhi, A.; Powers, A.; McGuire, M.; Seminotti, B.; Dobrowolski, S.F.; Reyes-Mugica, M.; Torok, K.S.; et al. ITCH deficiency clinical phenotype expansion and mitochondrial dysfunction. Mol. Genet. Metab. Rep. 2022, 33, 100932. [Google Scholar] [CrossRef]
- Olie, C.S.; O’Brien, D.P.; Jones, H.B.L.; Liang, Z.; Damianou, A.; Sur-Erdem, I.; Pinto-Fernandez, A.; Raz, V.; Kessler, B.M. Deubiquitinases in muscle physiology and disorders. Biochem. Soc. Trans. 2024, 52, 1085–1098. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.H.; Kang, J.S.; Yoo, K.; Jeong, J.; Park, I.; Park, J.H.; Rhee, J.; Jeon, S.; Jo, Y.W.; Hann, S.H.; et al. Bap1/SMN axis in Dpp4+ skeletal muscle mesenchymal cells regulates the neuromuscular system. JCI Insight 2022, 7, e158380. [Google Scholar] [CrossRef]
- Ramser, J.; Ahearn, M.E.; Lenski, C.; Yariz, K.O.; Hellebrand, H.; von Rhein, M.; Clark, R.D.; Schmutzler, R.K.; Lichtner, P.; Hoffman, E.P.; et al. Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy. Am. J. Hum. Genet. 2008, 82, 188–193. [Google Scholar] [CrossRef] [PubMed]
- Lambert-Smith, I.A.; Saunders, D.N.; Yerbury, J.J. The pivotal role of ubiquitin-activating enzyme E1 (UBA1) in neuronal health and neurodegeneration. Int. J. Biochem. Cell Biol. 2020, 123, 105746. [Google Scholar] [CrossRef]
- Khani, M.; Nafissi, S.; Shamshiri, H.; Moazzeni, H.; Taheri, H.; Sadeghi, M.; Salehi, N.; Chitsazian, F.; Elahi, E. Identification of UBA1 as the causative gene of an X-linked non-Kennedy spinal-bulbar muscular atrophy. Eur. J. Neurol. 2022, 29, 3556–3563. [Google Scholar] [CrossRef]
- Powis, R.A.; Karyka, E.; Boyd, P.; Come, J.; Jones, R.A.; Zheng, Y.; Szunyogova, E.; Groen, E.J.; Hunter, G.; Thomson, D.; et al. Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy. JCI Insight 2016, 1, e87908. [Google Scholar] [CrossRef] [PubMed]
- Bagga, P.; Singh, S.; Ram, G.; Kapil, S.; Singh, A. Diving into progress: A review on current therapeutic advancements in spinal muscular atrophy. Front. Neurol. 2024, 15, 1368658. [Google Scholar] [CrossRef] [PubMed]
- Nishio, H.; Niba, E.T.E.; Saito, T.; Okamoto, K.; Takeshima, Y.; Awano, H. Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment. Int. J. Mol. Sci. 2023, 24, 11939. [Google Scholar] [CrossRef] [PubMed]
- Harahap, N.I.F.; Nurputra, D.K.; Ar Rochmah, M.; Shima, A.; Morisada, N.; Takarada, T.; Takeuchi, A.; Tohyama, Y.; Yanagisawa, S.; Nishio, H. Salbutamol inhibits ubiquitin-mediated survival motor neuron protein degradation in spinal muscular atrophy cells. Biochem. Biophys. Rep. 2015, 4, 351–356. [Google Scholar] [CrossRef] [PubMed]
- Rhee, J.; Kang, J.S.; Jo, Y.W.; Yoo, K.; Kim, Y.L.; Hann, S.H.; Kim, Y.E.; Kim, H.; Kim, J.H.; Kong, Y.Y. Improved therapeutic approach for spinal muscular atrophy via ubiquitination-resistant survival motor neuron variant. J. Cachexia Sarcopenia Muscle 2024, 15, 1404–1417. [Google Scholar] [CrossRef] [PubMed]
- Bekes, M.; Langley, D.R.; Crews, C.M. PROTAC targeted protein degraders: The past is prologue. Nat. Rev. Drug Discov. 2022, 21, 181–200. [Google Scholar] [CrossRef] [PubMed]
- Yan, W.; Zhong, Y.; Hu, X.; Xu, T.; Zhang, Y.; Kales, S.; Qu, Y.; Talley, D.C.; Baljinnyam, B.; LeClair, C.A.; et al. Auranofin targets UBA1 and enhances UBA1 activity by facilitating ubiquitin trans-thioesterification to E2 ubiquitin-conjugating enzymes. Nat. Commun. 2023, 14, 4798. [Google Scholar] [CrossRef]
- Mirza, M.A.; Mahmood, S.; Hilles, A.R.; Ali, A.; Khan, M.Z.; Zaidi, S.A.A.; Iqbal, Z.; Ge, Y. Quercetin as a Therapeutic Product: Evaluation of Its Pharmacological Action and Clinical Applications-A Review. Pharmaceuticals 2023, 16, 1631. [Google Scholar] [CrossRef]
- Hensel, N.; Kubinski, S.; Claus, P. The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs. Front. Neurol. 2020, 11, 45. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bolado-Carrancio, A.; Tapia, O.; Rodríguez-Rey, J.C. Ubiquitination Insight from Spinal Muscular Atrophy—From Pathogenesis to Therapy: A Muscle Perspective. Int. J. Mol. Sci. 2024, 25, 8800. https://doi.org/10.3390/ijms25168800
Bolado-Carrancio A, Tapia O, Rodríguez-Rey JC. Ubiquitination Insight from Spinal Muscular Atrophy—From Pathogenesis to Therapy: A Muscle Perspective. International Journal of Molecular Sciences. 2024; 25(16):8800. https://doi.org/10.3390/ijms25168800
Chicago/Turabian StyleBolado-Carrancio, Alfonso, Olga Tapia, and José C. Rodríguez-Rey. 2024. "Ubiquitination Insight from Spinal Muscular Atrophy—From Pathogenesis to Therapy: A Muscle Perspective" International Journal of Molecular Sciences 25, no. 16: 8800. https://doi.org/10.3390/ijms25168800